FGP
ADMA icon

Freestone Grove Partners’s ADMA Biologics ADMA Stock Holding History

Freestone Grove Partners’s Portfolio ADMA Stock Details ADMA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$731K Buy
87,386
+35,931
+70% +$328K ﹤0.01% 585
2026
Q1 		$464K Buy
+51,455
New +$812K ﹤0.01% 609
2025
Q4 		– Sell
-30,519
Closed -$447K – 720
2025
Q3 		$447K Buy
+30,519
New +$523K ﹤0.01% 551
2025
Q1 		– Sell
-44,816
Closed -$769K – 574
2024
Q4 		$769K Buy
+44,816
New +$843K 0.01% 322

Other funds holding ADMA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $170B AUM 46.21% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
CP
Caligan Partners New York $2.13B AUM 758.65% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Freestone Grove Partners's ADMA Position: Q2 2026 in Review

Freestone Grove Partners increased its ADMA Biologics (ADMA) stake by 70% in Q2 2026, buying an estimated $328K and bringing the position to 87,386 shares worth $731K. The position accounts for ﹤0.01% of the portfolio, ranked #585.

Freestone Grove Partners first reported a position in ADMA in Q4 2024 and has held it in 4 quarters since. The position peaked at $769K in Q4 2024. 323 funds tracked by Wall St. Rank hold ADMA as of Q2 2026.

  • Freestone Grove Partners held 87,386 shares of ADMA Biologics worth $731K as of Q2 2026.
  • Freestone Grove Partners bought 35,931 ADMA Biologics shares in Q2 2026, an estimated $328K.
  • ADMA Biologics made up ﹤0.01% of Freestone Grove Partners's portfolio in Q2 2026, its #585 holding.
  • Freestone Grove Partners first reported a position in ADMA Biologics in Q4 2024 and has held it in 4 quarters since.
  • Freestone Grove Partners's ADMA Biologics position peaked at $769K in Q4 2024.
  • 323 funds tracked by Wall St. Rank held ADMA Biologics as of Q2 2026.

Based on Freestone Grove Partners's 13F filing for Q2 2026, filed 14 Aug 2026.